Answers are grounded in this paper and cite their sources.
Background: Chimeric antigen receptor T-cell (CAR-T cell) therapy has transformed the treatment landscape for relapsed or refractory hematologic malignancies. As the number of long-term survivors continues to grow, the recognition and management of late complications have become critical clinical priorities. The existing literature remains fragmented, with limited long-term prospective data and a lack of unified follow-up guidelines. Methods: A narrative review of the literature was conducted using PubMed, MEDLINE, and Google Scholar databases from inception through April 2026. Key search terms included long-term follow-up, survivorship, late effects, CAR-T cell therapy, chimeric antigen receptor, late complications, delayed cytopenias, hypogammaglobulinemia, secondary malignancies, immune reconstitution, and screening. This review synthesizes available evidence with expert consensus recommendations. Results: The review identifies prolonged cytopenias, hypogammaglobulinemia and infectious complications as the most prevalent late effects. Secondary myeloid neoplasms occur with a shorter latency than historically observed after conventional chemotherapy. Neurocognitive deficits following immune effector cell-associated neurotoxicity syndrome generally resolve within six months. Cardiovascular, endocrine, and reproductive late effects are emerging areas of concern with limited specific data. Conclusion: Structured, long-term, multidisciplinary follow-up is essential for CAR-T cell therapy recipients. This review provides recommendations for the long-term surveillance and management of these patients. Prospective registries and standardized screening protocols are urgently needed.
No takes yet. Share an insight, caveat, or question.
Fatobene et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: